Lithuania Dominates Seasonal Flu Vaccine Market in Baltic Region, States Renub Research in Topical Report Available at MarketPublishers.com
15 Mar 2017 • by Natalie Aster
LONDON – In the Baltic nations, Lithuania is the top market for seasonal influenza (flu) vaccine, grabbing the dominant market share; the country is followed by Latvia and Estonia. With respect to children immunisation, Lithuania and Latvia together accounted for close to 70% of the total market as of 2016; meantime, in adult immunisaiton segment, these two nations are poised to capture over 95% of the overall market by end-2022.
The market is being driven by the manufacturers’ plans to boost flu vaccine production, rising children and ageing population in the Baltic nations, and the surging healthcare spending share of the Baltic region’s GDP. However, regulatory challenges with new and innovative novel flu vaccines, dearth of healthcare infrastructure, and restricted reimbursement and access to the vaccines are amid the key challenges to the market growth.
Topical research report “Seasonal Influenza Vaccination Market in Lithuania, Estonia, Latvia” elaborated by Renub Research offers a comprehensive, unbiased analysis of the market across 3 Baltic states, namely Lithuania, Latvia and Estonia.
The study examines the seasonal flu vaccine market, carefully analysing in detail the market for the categories of children and adults. The report reviews seasonal flu vaccinated population in the three Baltic nations; gives an analysis of the seasonal flu vaccinated population broken down by children and adults, and offers detailed projections. The publication presents information on the number of vaccinated population (children & adults) and forecasts through to 2022. It provides the seasonal flu vaccine market share analysis for the Baltic countries discussed. Furthermore, the report limelights the major market driving factors and challenges.
More topical comprehensive market reports by Renub Research can be found at its page.